Search this website. You can use fund codes to locate specific funds

Guiding Principles for an Effective Board - Insights from Engagement

EOS publishes new white paper on board effectiveness

Fast reading

  • The paper focuses on the human, relational, and behavioural aspects of a board
  • We set out five guiding principles to help determine board effectiveness
  • Engagement provides valuable insights into how well a board is functioning

Investors care deeply about how well a company board is functioning. Getting this aspect of governance right makes it more likely that material risks and opportunities will be well managed. It follows that an effective board is best placed to secure a company’s long-term success.

Yet it remains difficult to assess board effectiveness. Disclosure on the measurable aspects of boards, such as board size, the age and tenure of directors, and the level of meeting attendance, is improving in some markets. While we welcome these developments, the set of standardised data points provided in company disclosures offer a limited picture of a board’s functionality. Ticking all the “good governance” boxes does not necessarily translate into good governance.

Engagement between investors and board directors provides a valuable opportunity to more deeply assess how well a board is functioning. This paper highlights the factors that we consider to be most important in determining board effectiveness. Our insights have been informed by engagement with directors from a wide range of sectors, markets and structures of corporate control.

The paper focuses on the human, relational, and behavioural aspects of a board, which are difficult to capture through a data point. There is increasing pressure on boards to get their approach right, given the high degree of scrutiny from regulators and the public, and the evolving corporate context. A board can interpret and apply the five guiding principles outlined in this paper according to a company’s particular requirements, with the ultimate goal of enhancing board effectiveness.

Related Insights

Burberry case study
Burberry has reaffirmed its commitment to find alternatives to incinerating surplus stock in the midst of the coronavirus pandemic and set a science-based carbon reduction target.
The coronavirus and the race for a vaccine
With the coronavirus pandemic set to continue without an effective and widely-available vaccine, all eyes are on the pharmaceutical sector.
Mizuho Financial Group case study
Mizuho has made a commitment to ending financing of new coal-fired power plants and reducing exposure to coal-fired power plants to zero by 2050, the only Japanese bank to makes such a commitment.
A voting season like no other
With many companies opting for virtual shareholder meetings, how did investors ensure their concerns about climate change, diversity and human rights risks were addressed?
Antimicrobial resistance and the challenge for pharmaceutical companies
A lack of research and development into new antibiotic classes compounds the serious threat that antimicrobial resistance poses to public health.
Repsol case study
Repsol became the first oil and gas company to commit to a net-zero goal by 2050, supported by a decarbonisation pathway with interim targets, setting a higher benchmark for the industry. EOS has engaged with the company since 2013 on its climate action and targets.

EOS Client Service and Business Development

Amy D’Eugenio,
Head of Client Service and Business Development, EOS